Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth

Summary

GBI Research in its present report "Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth" describes generic market in antiviral therapeutics. This report covers antiviral therapeutics including HIV therapeutics, Hepatitis therapeutics, Herpes therapeutics, CMV therapeutics and Influenza therapeutics. Generics in antiviral market are forecast to grow at a CAGR of 10.5% during 2010-2018, largely due to series of patent expiries in the antiviral market. In 2010 generic HIV/AIDS therapeutic market sales contributes 46% market share in the total generic antiviral therapeutic market followed by generic herpes therapeutic market with 39.6% of market share. It is estimated that in 2010, generics accounted for 18.9% of market share in global antivirals market, and this market share is forecast to grow and reach 29.2% by 2018.

Generics in global antivirals market are estimated to be $4.2 billion in 2010 and are forecast to grow at a CAGR of 10.5% and reach $9.2 billion by 2018. From 2004, the market grew at a CAGR of 21.1% to reach $4.2 billion in 2010. Global generic antiviral market is comprised of revenues generated by various generic antiviral drugs. In 2010, it is estimated that generics in HIV market accounted for largest market share in total generic antivirals market. Generics in HIV market accounted for 46% of market share in total generic antivirals market in 2010, while generic herpes therapeutics accounted for 39.6% of market share. Generic influenza therapeutics accounted for 1% of total market share. Generic CMV market holds about 9.6% of share in total antiviral generic market, while generic hepatitis market accounted for only 3.9% of market share.

Series of patent expiries of key antiviral drugs will positively impact the market. Increase in patient population, reforms in government policies towards the use of generic drugs could be other major drivers of the market during the forecast period.

GBI Research projects that global generic HIV market will grow at a CAGR of 6.7% during 2010-2018. Growth in the market could be attributed to loss of patent exclusivity of key antiviral drugs. The market is currently dominated by products such as zidovudine, didanosine, stavudine and lamivudine. Launch of Combivir (lamivudine/Zidovudine) is expected soon, which can significantly influence the market.

GBI Research forecast's that global generic herpes market will grow at a CAGR of 9% during 2010-2018. Global generic herpes therapeutics market grew at a rapid rate of 32.4% from 2004 to 2010. The market revenue during this period was driven primarily by generic product such as acyclovir. In 2009, after patent expiry of Valtrex (valacyclovir), its generic equivalents were launched. In 2010, Famvir (famciclovir), potent antiviral from Novartis lost its patent exclusivity and its generic equivalents are currently available. In April, 2011, Mylan launched generic version of famciclovir.

Scope

• Data and analysis on the global generics in antivirals market
• Market forecasts for the global generics in antivirals market until 2018
• Market Data on geographical landscape including country wise coverage, cost of therapy, market size and market share.
• Key drivers and restraints that have created significant impact on the market.
• Competitive landscape of the global generics in antivirals market including top companies profiles. The key companies studied in this report are Teva Pharmaceuticals, Aurobindo Pharma, Mylan Inc and Watson Pharmaceuticals.
• Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2011 in the global generics in antivirals market.

Reasons to buy

The report will aid business development and marketing executives strategizing their product launches -

• Build effective strategies to launch their generics antiviral products by identifying potential geographies.
• Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
• Develop key strategic initiatives by studying the key strategies of top competitors.
• Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

Executive Summary

HIV Generics Take Over the Antivirals Market.

Generics are predicted to take over the antiviral drugs market, especially in the case of HIV medication, as a series of patent expiries will open opportunities for ambitious companies to seize huge revenue, according to a new report by healthcare experts GBI Research.

The new report* states that an increase in the patient population and reforms in government policies will work together to encourage the rise of generic pharmaceutical powers.

Government policies include the need for prior authorization in order to dispense branded drugs that have generic alternatives, while further incentives are available from Pharmacy Benefit Managers (PBM) for dispensing generic drugs. These kinds of regulatory changes and financial benefits could act as significant drivers of the market during the forecast period.

While it is estimated that, in 2010, generics accounted for 18.9% of the market share in the global antivirals market, this market share is forecast to grow to reach 29.2% by 2018. This is largely due to a series of patent expiries expected to hit the antiviral market, which will act to raise the value of generic antiviral drugs to over $9 billion by 2018.

Generics in the HIV market in particular accounted for an estimated majority market share of 46% in the total generic antivirals market during 2010. HIV generics are expected to create a boom in the market, due to a loss of patent exclusivity for key antiviral drugs.

The generic market is currently dominated by products such as zidovudine, didanosine, stavudine and lamivudine. However, many major patent expiries are expected during the forecast period, including Sustiva (efavirenz) and Kaletra (lopinavir + ritonavir) in 2013, Prezista (darunavir ethanolate) in 2014, and major Nucleoside Reverse Transcriptase Inhibitors (NRTIs) such as Trizivir (abacavir sulphate/lamivudine/zidovudine), Epzicom (lamivudine and abacavir) and Emtriva (emtricitabine) in 2016.

By 2018, billions of dollars' worth of industry revenue will be lost from the expiry of these brand name products, and the race will be on for generics manufacturers to create new superstar drugs to make the most of this unmet need in the market. Generics within the antiviral market are forecast to grow at a CAGR of 10.5% during 2010-2018.

In December 2011, Teva launched generic Combivir in the US market as a combination tablet containing lamivudine and zidovudine, indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Combivir had annual sales of approximately $556m in 2010, based on the annual report.

Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth

This report describes generic market in antiviral therapeutics, and covers antiviral therapeutics including HIV therapeutics, Hepatitis therapeutics, Herpes therapeutics, CMV therapeutics and Influenza therapeutics.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

• 1.1. List of Tables
• 1.2. List of Figures

2. Introduction

3. Generics in Antivirals Market to 2018-Market Overview

• 3.1. Introduction
• 3.2. Generic in Antivirals Market, Global Revenues
  • 3.2.1. Revenue
  • 3.2.2. Annual Cost of Treatment
  • 3.2.3. Treatment Usage Pattern
  • 3.2.4. Drivers and Restraints for Generic Antiviral Market

4. Generics in Antivirals Market to 2018-Geographical Landscape

• 4.1. The US
  • 4.1.1. Revenue
  • 4.1.2. Treatment Usage Pattern
• 4.2. Top Five Countries of Europe
  • 4.2.1. Revenue
  • 4.2.2. Treatment Usage Pattern
• 4.3. Japan
  • 4.3.1. Revenue
  • 4.3.2. Treatment Usage Pattern

5. Generics in Antiviral Market to 2018-Therapeutic Landscape

• 5.1. Global Generic HIV Therapeutics Market
  • 5.1.1. Introduction
  • 5.1.2. Revenue
  • 5.1.3. Annual Cost of Treatment
  • 5.1.4. Treatment Flow Algorithm
  • 5.1.5. Treatment Usage Pattern
  • 5.1.6. Drivers and Restraints for Generic HIV Market
• 5.2. Global Generic Hepatitis Therapeutics Market
  • 5.2.1. Introduction
  • 5.2.2. Revenue
  • 5.2.3. Annual Cost of Treatment
  • 5.2.4. Treatment Flow Algorithm
  • 5.2.5. Treatment Usage Pattern
  • 5.2.6. Drivers and Restraints for Generic Hepatitis Market
• 5.3. Global Generic Herpes Therapeutics Market
  • 5.3.1. Introduction
  • 5.3.2. Revenue
  • 5.3.3. Annual Cost of Treatment
  • 5.3.4. Treatment Flow Algorithm
  • 5.3.5. Treatment Usage Pattern
  • 5.3.6. Drivers and Restraints for Generics in Herpes Therapeutics Market
• 5.4. Global Generic Cytomegalovirus Therapeutics Market
  • 5.4.1. Introduction
  • 5.4.2. Revenue
  • 5.4.3. Annual Cost of Treatment
  • 5.4.4. Treatment Usage Pattern
  • 5.4.5. Drivers and Restraints for Cytomegalovirus Therapeutics Market
• 5.5. Global Generic Influenza Market
  • 5.5.1. Introduction
  • 5.5.2. Revenue
  • 5.5.3. Annual Cost of Treatment
  • 5.5.4. Treatment Flow Algorithm
  • 5.5.5. Treatment Usage Pattern
  • 5.5.6. Drivers and Restraints for Influenza Therapeutics Market

6. Generics in Antivirals Market to 2018-Major Marketed Drugs Analysis

• 6.1. Major Generic Drugs in Antivirals Market
  • 6.1.1. Ribavirin
  • 6.1.2. Acyclovir
  • 6.1.3. Valacyclovir
  • 6.1.4. Famciclovir
  • 6.1.5. Penciclovir
  • 6.1.6. Didanosine
  • 6.1.7. Lamivudine
  • 6.1.8. Stavudine
  • 6.1.9. Zidovudine
  • 6.1.10. Zalcitabine
  • 6.1.11. Amantadine
  • 6.1.12. Rimantadine
  • 6.1.13. Ganciclovir
  • 6.1.14. Foscarnet
• 6.2. Major Marketed Products Expecting Loss of Patent Exclusivity
  • 6.2.1. Introduction
  • 6.2.2. Baraclude
  • 6.2.3. Viread
  • 6.2.4. Combivir
  • 6.2.5. Sustiva
  • 6.2.6. Kaletra
  • 6.2.7. Reyataz
  • 6.2.8. Epzicom
  • 6.2.9. Prezista
  • 6.2.10. Valcyte
  • 6.2.11. Tamiflu
  • 6.2.12. Atripla
  • 6.2.13. Truvada

7. Generics in Antivirals Market to 2018-Competitive Landscape

• 7.1. Competitive Profiling
  • 7.1.1. Teva Pharmaceuticals
  • 7.1.2. Aurobindo Pharma Ltd
  • 7.1.3. Watson Pharmaceuticals
  • 7.1.4. Mylan Inc

8. Generics in Antivirals Market to 2018-Strategic Consolidations

• 8.1. Generics in Antivirals Market: Major Deals
  • 8.1.1. Gilead Sciences Extends Licensing Agreement with Matrix Laboratories for Tenofovir, Elvitegravir, Cobicistat and Quad
  • 8.1.2. Bristol-Myers Squibb Enters Into Co-Marketing Agreement with Matrix Laboratories
  • 8.1.3. Tibotec Pharmaceuticals Enters Into Licensing Agreement with Matrix Laboratories for TMC278
  • 8.1.4. Watson Pharmaceuticals Acquires Specifar Pharmaceuticals
  • 8.1.5. Watson Enters into Licensing Agreement with Natco
  • 8.1.6. Apotex Acquires Lareq Pharma from Industria Quimica Y Farmaceutica
  • 8.1.7. Apotex Acquires Topgen from Zambon
  • 8.1.8. Teva Pharmaceutical Industries Acquires Taiyo Pharmaceutical Industry
  • 8.1.9. Teva Pharmaceutical Industries Acquires Corporacion Infarmasa
  • 8.1.10. Teva Pharmaceutical Industries Completes Acquisition of ratiopharm
  • 8.1.11. Teva Pharmaceutical Acquires Barr Pharmaceuticals
  • 8.1.12. Teva Pharmaceutical Industries Signs Joint Venture Agreement with Kowa Company
  • 8.1.13. Teva Pharmaceutical Acquires Bentley Pharmaceuticals

9. Generics in Antivirals Market to 2018-Appendix

• 9.1. Market Definitions
• 9.2. Abbreviations
• 9.3. Sources
• 9.4. Research Methodology
  • 9.4.1. Coverage
  • 9.4.2. Secondary Research
  • 9.4.3. Primary Research
  • 9.4.4. Forecast
  • 9.4.5. Expert Panel Validation
• 9.5. Contact Us
• 9.6. Disclaimer

List of Tables

• Table 1: Generics in Antivirals Market, Global, Revenue by Indication ($m), 2004-2010
• Table 2: Generics in Antivirals Market, Global, Revenue Forecast by Indication ($m), 2010-2018
• Table 3: Generics in Antivirals Market, Global, Revenue ($bn), 2004-2010
• Table 4: Generics in Antivirals Market, Global, Revenue Forecast ($bn), 2010-2018
• Table 5: Generics in Antivirals Market, Global, Revenue by Geography ($m), 2004-2010
• Table 6: Generics in Antivirals Market, Global, Revenue Forecast by Geography ($m), 2010-2018
• Table 7: Generics in Antivirals Market, Global, Annual Cost of Treatment ($), 2004-2010
• Table 8: Generics in Antivirals Market, Global, Annual Cost of Treatment ($), 2010-2018
• Table 9: Generics in Antivirals Market, Global, Treatment Usage Pattern (millions), 2004-2018
• Table 10: Generics in Antivirals Market, Global, Treatment Usage Pattern (millions), 2010-2018
• Table 11: Generics in Antivirals Market, The US, Revenue ($m), 2004-2010
• Table 12: Generics in Antivirals Market, The US, Revenue Forecast ($m), 2010-2018
• Table 13: Generics in Antivirals Market, The US, Treatment Usage Pattern (millions), 2004-2010
• Table 14: Generics in Antivirals Market, The US, Treatment Usage Pattern (millions), 2010-2018
• Table 15: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue ($m), 2004-2010
• Table 16: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue Forecast ($m), 2010-2018
• Table 17: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue by Geography ($m), 2004-2010
• Table 18: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue Forecast by Geography ($m), 2010-2018
• Table 19: Generics in Antivirals Market, The Top Five Countries of Europe, Treatment Usage Pattern (millions), 2004-2010
• Table 20: Generics in Antivirals Market, The Top Five Countries of Europe, Treatment Usage Pattern (millions), 2010-2018
• Table 21: Generics in Antivirals Market, Japan, Revenue ($m), 2004-2010
• Table 22: Generics in Antivirals Market, Japan, Revenue Forecast ($m), 2010-2018
• Table 23: Generics in Antivirals Market, Japan, Treatment Usage Pattern (millions), 2004-2010
• Table 24: Generics in Antivirals Market, Japan, Treatment Usage Pattern (millions), 2010-2018
• Table 25: Generics in HIV Market, Global, Revenue ($m), 2004-2010
• Table 26: Generics in HIV Market, Global, Revenue Forecast ($m), 2010-2018
• Table 27: Generics in HIV Market, Global, Patent Expiry of Major Products, 2010-2018
• Table 28: Generics in HIV Market, Global, Revenue by Geography ($m), 2004-2010
• Table 29: Generics in HIV Market, Global, Revenue Forecast by Geography ($m), 2010-2018
• Table 30: Generics in HIV Market, Global, Annual Cost of Treatment ($), 2004-2010
• Table 31: Generics in HIV Market, Global, Annual Cost of Treatment ($), 2010-2018
• Table 32: Generics in HIV Market, Global, Treatment Usage Pattern ('000), 2004-2010
• Table 33: Generics in HIV Market, Global, Treatment Usage Pattern ('000), 2010-2018
• Table 34: Generics in Hepatitis Market, Global, Revenue ($m), 2004-2010
• Table 35: Generics in Hepatitis Market, Global, Revenue Forecast ($m), 2010-2018
• Table 36: Generics in Hepatitis Market, Global, Patent Expiry of Major Products, 2010-2018
• Table 37: Generics in Hepatitis Market, Global, Revenue by Geography ($m), 2004-2010
• Table 38: Generics in Hepatitis Market, Global, Revenue Forecast by Geography ($m), 2010-2018
• Table 39: Generics in Hepatitis Market, Global, Annual Cost of Treatment ($), 2004-2010
• Table 40: Generics in Hepatitis Market, Global, Annual Cost of Treatment ($), 2010-2018
• Table 41: Generics in Hepatitis Market, Global, Treatment Usage Pattern ('000), 2004-2010
• Table 42: Generics in Hepatitis Market, Global, Treatment Usage Pattern ('000), 2010-2018
• Table 43: Generics in Herpes Therapeutics Market, Global, Revenue ($m), 2004-2010
• Table 44: Generics in Herpes Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018
• Table 45: Generics in Herpes Therapeutics Market, Revenue by Geography ($m), 2004-2010
• Table 46: Generics in Herpes Therapeutics Market, Revenue Forecast by Geography ($m), 2010-2018
• Table 47: Generics in Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010
• Table 48: Generics in Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
• Table 49: Generics in Herpes Therapeutics Market, Global, Treatment Usage Pattern (millions), 2004-2010
• Table 50: Generics in Herpes Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2018
• Table 51: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue ($m), 2004-2010
• Table 52: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018
• Table 53: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue by Geography ($m), 2004-2010
• Table 54: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue Forecast by Geography ($m), 2010-2018
• Table 55: Generics in Cytomegalovirus Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010
• Table 56: Generics in Cytomegalovirus Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
• Table 57: Generics in Cytomegalovirus Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004-2010
• Table 58: Generics in Cytomegalovirus Therapeutics Market, Global, Treatment Usage Pattern ('000), 2010-2018
• Table 59: Generics in Influenza Therapeutics Market, Global, Revenue ($m), 2004-2010
• Table 60: Generics in Influenza Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018
• Table 61: Generics in Influenza Therapeutics Market, Global, Revenue by Geography ($m), 2004-2010
• Table 62: Generics in Influenza Therapeutics Market, Global, Revenue Forecast by Geography ($m), 2010-2018
• Table 63: Generics in Influenza Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010
• Table 64: Generics in Influenza Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
• Table 65: Generics in Influenza Therapeutics Market, Global, Treatment Usage Pattern (millions), 2004-2010
• Table 66: Generics in Influenza Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2018
• Table 67: Generics in Influenza Therapeutics Market, List of Marketed Products Expecting Loss of Patent Exclusivity

List of Figures

• Figure 1: Generics in Antivirals Market, Global, Revenue Forecast by Indication ($m), 2004-2018
• Figure 2: Generics in Antivirals Market, Global, Revenue Forecast ($bn), 2004-2018
• Figure 3: Generics in Antivirals Market, Global, Revenue Forecast by Geography ($m), 2004-2018
• Figure 4: Generics in Antivirals Market, Global, Annual Cost of Treatment ($), 2004-2018
• Figure 5: Generics in Antivirals Market, Global, Treatment Usage Pattern (millions), 2004-2018
• Figure 6: Generics in Antivirals Market, Global, Drivers and Restraints
• Figure 7: Generics in Antivirals Market, The US, Revenue Forecast ($m), 2004-2018
• Figure 8: Generics in Antivirals Market, The US, Treatment Usage Pattern (millions), 2004-2018
• Figure 9: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue Forecast ($m), 2004-2018
• Figure 10: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue Forecast by Geography ($m), 2004-2018
• Figure 11: Generics in Antivirals Market, The Top Five Countries of Europe, Treatment Usage Pattern (millions), 2004-2018
• Figure 12: Generics in Antivirals Market, Japan, Revenue Forecast ($m), 2004-2018
• Figure 13: Generics in Antivirals Market, Japan, Treatment Usage Pattern (millions), 2004-2018
• Figure 14: Generics in HIV Market, Global, Revenue Forecast ($m), 2004-2018
• Figure 15: Generics in HIV Market, Global, Revenue Forecast by Geography ($m), 2004-2018
• Figure 16: Generics in HIV Market, Global, Annual Cost of Treatment ($), 2004-2018
• Figure 17: Generics in HIV Market, HIV/AIDS Treatment Flow Algorithm, 2011
• Figure 18: Generics in HIV Market, Global, Treatment Usage Pattern ('000), 2004-2018
• Figure 19: Generics in HIV Market, Global, Drivers and Restraints
• Figure 20: Generics in Hepatitis Market, Global, Revenue Forecast ($m), 2004-2018
• Figure 21: Generics in Hepatitis Market, Global, Revenue Forecast by Geography ($m), 2004-2018
• Figure 22: Generics in Hepatitis Market, Global, Annual Cost of Treatment ($), 2004-2018
• Figure 23: Generics in Hepatitis Market, Hepatitis Treatment Flow Pathway, 2011
• Figure 24: Generics in Hepatitis Market, Global, Treatment Usage Pattern (millions), 2004-2018
• Figure 25: Generics in Hepatitis Market, Global, Drivers and Restraints
• Figure 26: Generics in Herpes Therapeutics Market, Global, Revenue Forecast ($m), 2004-2018
• Figure 27: Generics in Herpes Therapeutics Market, Revenue Forecast by Geography ($m), 2004-2018
• Figure 28: Generics in Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
• Figure 29: Generics in Herpes Therapeutics Market, Global, Treatment Algorithm,2011
• Figure 30: Generics in Herpes Therapeutics Market, Global, Treatment Usage Pattern (millions), 2004-2018
• Figure 31: Generics in Herpes Therapeutics, Global, Drivers and Restraints
• Figure 32: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue Forecast ($m), 2004-2018
• Figure 33: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue Forecast by Geography ($m), 2004-2018
• Figure 34: Generics in Cytomegalovirus Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
• Figure 35: Generics in Cytomegalovirus Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004-2018
• Figure 36: Generics in Cytomegalovirus Therapeutics Market, Global, Drivers and Restraints
• Figure 37: Generics in Influenza Therapeutics Market, Global, Revenue Forecast ($m), 2004-2018
• Figure 38: Generics in Influenza Therapeutics Market, Global, Revenue Forecast by Geography ($m), 2004-2018
• Figure 39: Generics in Influenza Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
• Figure 40: Generics in Influenza Therapeutics Market, Treatment Flow Algorithm for Influenza, 2011
• Figure 41: Generics in Influenza Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004-2018
• Figure 42: Generics in Influenza Therapeutics Market, Global, Drivers and Restraints
• Figure 43: Generics in Antiviral Market, Teva Pharmaceuticals SWOT Profile, 2011
• Figure 44: Generics in Antiviral Market, Aurobindo Pharma SWOT Profile, 2011
• Figure 45: Generics in Antiviral Market, Watson Pharmaceuticals SWOT Profile, 2011
• Figure 46: Generics in Antiviral Market, Mylan Inc SWOT Profile, 2011
• Figure 47: GBI Research Market Forecasting Model